Carsten Boess
Director/Board Member at ROCKET PHARMACEUTICALS, INC.
Net worth: - $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Troy Wilson | M | 55 | 12 years | |
Karl Peggs | M | 57 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 8 years |
Edwin Moses | M | 69 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 6 years |
Iraj Ali | M | 48 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 6 years |
Stephen Biggar | M | 53 | 13 years | |
Eben Tessari | M | 42 | 10 years | |
Lars Fruergaard Jorgensen | M | 58 | 33 years | |
David Southwell | M | 63 | 10 years | |
Barry Quart | M | 67 | 12 years | |
Sarah Boyce | F | 52 | 5 years | |
John Militello | M | 50 | 6 years | |
Eric B. Mosbrooker | M | 46 | 3 years | |
Derek DiRocco | M | 43 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 4 years |
Michael Megna | M | 53 | 6 years | |
Rod Wong | M | 47 | 6 years | |
Mark Ragosa | M | 50 | 6 years | |
Kathleen Gallagher | F | - | 3 years | |
Arthur Levin | M | 70 | 11 years | |
Gaurav D. Shah | M | 49 | 6 years | |
John W. Wallen | M | 66 | 12 years | |
Sanj Patel | M | 54 | 9 years | |
Michael Giordano | M | 66 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 6 years |
Tracey McCain | F | 56 | 6 years | |
Noreen Henig | M | 59 | 5 years | |
Felix Baker | M | 55 | 9 years | |
Sergio Quezada | M | 49 | 4 years | |
Martin Wilson | M | 47 | 3 years | |
Jonathan Schwartz | M | 60 | 8 years | |
R. Woods | M | 57 | 1 years | |
Melissa Manno | F | - | 9 years | |
Gayatri R. Rao | M | - | 6 years | |
Tamar Thompson | F | 50 | 3 years | |
Daniel Hood | M | - | - | |
Kinnari Patel | M | 46 | 6 years | |
Mark White | M | 57 | 1 years | |
Kim Popovits | F | 65 | 6 years | |
Jean Kim | F | 50 | 3 years | |
Richard Levy | M | 66 | 5 years | |
Edward Kaye | M | 75 | 5 years | |
Margareta Elisabeth Björk | M | 63 | 4 years | |
Fady Malik | M | 59 | 2 years | |
Naveen Yalamanchi | M | 47 | 6 years | |
Karsten Munk Knudsen | M | 53 | 25 years | |
Henrik Ehlers Wulff | M | 54 | 25 years | |
Pedro Granadillo | M | 77 | 6 years | |
Thomas Malley | M | 55 | 8 years | |
Bernhard R. M. Ehmer | M | 69 | 2 years | |
Gotham Makker | M | 50 | 6 years | |
Michael MacLean | M | 58 | 4 years | |
Robert Coutts | M | 40 | 4 years | |
Teresa McCarthy | F | 60 | 4 years | |
Shree Patel | M | - | - | |
Tariq Ahmed | M | - | 4 years | |
Edward Samuel | M | - | 2 years | |
Liz Elmhirst | F | - |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | - |
James Taylor | M | - | 2 years | |
Ross Moat | M | 43 | 5 years | |
Julie O'Neill | F | 58 | 3 years | |
Dara Henry | M | - |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | - |
Martin Lange | M | 54 | 22 years | |
Martina Struck | M | - | 6 years | |
Martin Murphy | M | 55 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | - |
Steven G. Hughes | M | 57 | 2 years | |
W. Flanagan | M | 62 | 3 years | |
Katrine Sperling | F | - | 22 years | |
Camilla Sylvest | F | 52 | 28 years | |
Elisa Petris | M | 45 |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | 8 years |
Maziar Mike Doustdar | M | 54 | 32 years | |
Mayo Pujols | M | 55 | 2 years | |
John Paolini | M | 59 | 8 years | |
Rogier Rooswinkel | M | - |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Thomas Beetham | M | 55 | 8 years | |
Christopher Heberlig | M | 49 | 12 years | |
Stephen Mahoney | M | 53 | 7 years | |
Brian Batchelder | M | - | - | |
Mayur Kasetty | M | - | 4 years | |
Rasmus Holm-Jorgensen | M | 53 | 11 years | |
Jakob Riis | M | 58 | 21 years | |
Carsten Hellmann | M | 60 | - | |
Deirdre O’Donnell | F | - | - | |
Brendan Classon | M | - | - | |
Michael Martin | M | 50 | 5 years | |
Lynn A. Taylor | F | - |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | - |
Mark Goldberg | M | 69 | 6 years | |
Todd Brady | M | 45 | 5 years | |
Thomas Tisch | M | 69 | 3 years | |
Steven T. Sobieski | M | 66 | 10 years | |
John T. Garibotto | M | 59 | 8 years | |
Mads Krogsgaard Thomsen | M | 63 | 30 years | |
Jesper Brandgaard | M | 60 | 20 years | |
Sten Scheibye | M | 72 | 10 years | |
Kurt Anker Nielsen | M | 78 | 13 years | |
Stephen Davis | M | 63 | 4 years | |
Harry Penner | M | 78 | 8 years | |
Peter Wirth | M | 73 | 3 years | |
Sally Crawford | F | 70 | 13 years | |
Lars Robert Boesgaard | M | 55 | 5 years | |
Larry L. Mathis | M | 80 | 10 years | |
Regina Sommer | F | 66 | 9 years | |
Joseph Zakrzewski | M | 60 | 9 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 67 | 67.00% |
United Kingdom | 19 | 19.00% |
Denmark | 14 | 14.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Carsten Boess
- Personal Network